Christopher C. Broder, BS (1983), MS (1985), Florida Institute of Technology, and PhD (1989), University of Florida (Molecular-pathogenesis of Group A streptococci). National Research Council Research Associate, Laboratory of Viral Diseases, NIAID, NIH (HIV-1 membrane fusion and cell entry) 1989-96. Faculty: Department of Microbiology and Immunology at Uniformed Services University (USU) (1996); presently Professor. Research: virus-mediated membrane fusion, infection, receptor discovery, antiviral countermeasures, and serology-based virus surveillance. Current areas: henipaviruses (Nipah, Hendra, others); filoviruses (Ebola, others), and bat lyssaviruses. Contributions: the discovery of HIV-1 coreceptors CXCR4 and CCR5; the development of the first oligomeric HIV-1 gp140 vaccine candidate; the Hendra/Nipah soluble-G glycoproteins; one version of (HeV-sG) Equivac® HeV (Zoetis, Inc.), the first commercialized BSL-4 agent vaccine now in clinical trial as Nipah vaccine; the discovery of the entry receptors for Nipah and Hendra (ephrins); and the anti-Hendra/Nipah mAb m102.4, used in emergencies by 18 people. Honors: the AAAS Newcomb Cleveland Prize; CSIRO Chairman’s Medal—Australia's national science agency; 2013 and 2019 Federal Laboratory Consortium (FLC) Awards for Excellence in Technology Transfer; 2020 FLC Impact Award; Military Health System Research Symposium 2020 Outstanding Individual Research Accomplishment Award; and 2021 Outstanding Research Accomplishment Team Award.